FibroBiologics, Inc. Common Stock (FBLG) vs Moleculin Biotech, Inc. (MBRX)
A side-by-side comparison of FibroBiologics, Inc. Common Stock and Moleculin Biotech, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
FBLG
FibroBiologics, Inc. Common Stock
$1.21HealthcareDelayed quote: Oct 6, 2026, 10:52 AM EDT
MBRX
Moleculin Biotech, Inc.
$0.45HealthcareDelayed quote: Oct 6, 2026, 10:54 AM EDT
Total return — FBLG vs MBRX
growth of $100 · dividends reinvested · last 3yFBLG -99.8% (-87.3%/yr)MBRX -99.7% (-86.3%/yr)MBRX compounded faster over this window
FBLG MBRX
FBLG vs MBRX: by the numbers
- •FBLG is the larger company ($3M vs $2M market cap).
Metrics side by side
Valuation
| Metric | FBLG | MBRX |
|---|---|---|
| P/B ratio | 0.55 | 0.21 |
Profitability
| Metric | FBLG | MBRX |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -391.26% | -261.73% |
| ROIC | -286.46% | -242.25% |
Growth (annualized)
| Metric | FBLG | MBRX |
|---|---|---|
| Total return CAGR (5Y) | N/A | -78.48% |
Go deeper
Dig into the metrics
FibroBiologics, Inc. Common Stock ROEMoleculin Biotech ROEFibroBiologics, Inc. Common Stock operating marginMoleculin Biotech operating marginFibroBiologics, Inc. Common Stock revenue growthMoleculin Biotech revenue growthFibroBiologics, Inc. Common Stock free cash flowMoleculin Biotech free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.